Goldman Sachs initiated coverage of 89bio (ETNB) with a Neutral rating and $11 price target 89bio is a late-stage clinical company focused on ...
What began as an innocent idea 50 years ago has now become a mainstay within the Forest Hills School District.
A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landsca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback